[The effect of low and high molecular weight dextrans on selected lipid parameters in serum. Part 3].
After a ten-day treatment of 21 patients with low molecular weight dextran (MW = 40,000), a decrease in the plasma concentrations of total cholesterol of 25%, LDL-cholesterol of 32% and apoprotein B of 22% was observed. The HDL fraction only showed a reduction of 10%. These dextran effects were dose-dependent. During the post-treatment period of 20 days a continuous increase in the lipid parameters to the preinfusion values was demonstrated. Dextran caused stronger lipid changes in HLP patients than in normolipaemics.
Rühlmann
C
C
Abteilung Kardiologie/Angiologie, Universität Leipzig.
Koksch
M
M
Hohdorf
K
K
Kuklinski
B
B
D016632:Apolipoprotein A-I / Q000378:metabolism; D001055:Apolipoproteins B / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003911:Dextrans / Q000008:administration & dosage*; D006438:Hemodilution; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D007262:Infusions, Intravenous; D008055:Lipids / Q000097:blood*; D008970:Molecular Weight; D014280:Triglycerides / Q000097:blood
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003911:Dextrans; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol